EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cancer–stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies

Marie-Anne Goyette, Laura E Stevens, Carolyn R DePinho, Marco Seehawer, Jun Nishida, Zheqi Li, Callahan M Wilde, Rong Li, Xintao Qiu, Alanna L Pyke, Stephanie Zhao, Klothilda Lim und 7 weitere

Proceedings of the National Academy of Sciences · 2024

DOI: 10.1073/pnas.2322688121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Marie-Anne Goyette und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215. Hauptthemen laut MEDLINE: Breast Neoplasms, Brain Neoplasms, Drug Resistance, Neoplasm, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Foundation for Cancer Research (NFCR), HHS | NIH | National Cancer Institute (NCI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brain metastatic breast cancer is particularly lethal largely due to therapeutic resistance. Almost half of the patients with metastatic HER2-positive breast cancer develop brain metastases, representing a major clinical challenge. We previously described that cancer-associated fibroblasts are an important source of resistance in primary tumors. Here, we report that breast cancer brain metastasis stromal cell interactions in 3D cocultures induce therapeutic resistance to HER2-targeting agents, particularly to the small molecule inhibitor of HER2/EGFR neratinib. We investigated the underlying mechanisms using a synthetic Notch reporter system enabling the sorting of cancer cells that directly interact with stromal cells. We identified mucins and bulky glycoprotein synthesis as top-up-regulated genes and pathways by comparing the gene expression and chromatin profiles of stroma-contact and no-contact cancer cells before and after neratinib treatment. Glycoprotein gene signatures were also enriched in human brain metastases compared to primary tumors. We confirmed increased glycocalyx surrounding cocultures by immunofluorescence and showed that mucinase treatment increased sensitivity to neratinib by enabling a more efficient inhibition of EGFR/HER2 signaling in cancer cells. Overexpression of truncated MUC1 lacking the intracellular domain as a model of increased glycocalyx-induced resistance to neratinib both in cell culture and in experimental brain metastases in immunodeficient mice. Our results highlight the importance of glycoproteins as a resistance mechanism to HER2-targeting therapies in breast cancer brain metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBrain NeoplasmsDrug Resistance, NeoplasmErb-b2 Receptor Tyrosine KinasesGlycocalyxStromal CellsQuinolinesHumansFemaleAnimalsCell Line, TumorMiceCell CommunicationCoculture TechniquesMucin-1Signal TransductionErbB Receptors

Stichwörter der Autor:innen

HER2brain metastasisbreast cancerresistancestroma

Substanzen

Erb-b2 Receptor Tyrosine KinasesQuinolinesMucin-1ErbB ReceptorsERBB2 protein, humanneratinib

Autor:innen und Institutionen

  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.
  • Department of Medicine, Harvard Medical School, Boston, MA 02115.
  • Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115.
  • Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
  • Department of Chemistry, Stanford University, Stanford, CA 94305.
  • Center for Bioengineering and Tissue Regeneration, University of California San Francisco, San Francisco, CA 94143.

ORCID-Profile: Carolyn R Bertozzi, Valerie M Weaver, Kornelia Polyak

Förderung

  • NCI NIH HHS
  • National Foundation for Cancer Research (NFCR)
  • HHS | NIH | National Cancer Institute (NCI)
  • Canadian Government | Canadian Institutes of Health Research (CIHR)

Zitieren

APA

Goyette, M. A., Stevens, L. E., DePinho, C. R., Seehawer, M., Nishida, J., Li, Z., Wilde, C. M., Li, R., Qiu, X., Pyke, A. L., Zhao, S., Lim, K., Tender, G. S., Northey, J. J., Riley, N. M., Long, H. W., Bertozzi, C. R., Weaver, V. M., & Polyak, K. (2024). Cancer–stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2322688121

Vancouver

Goyette MA, Stevens LE, DePinho CR, Seehawer M, Nishida J, Li Z, et al. Cancer–stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2322688121

BibTeX
@article{Goyette2024,
  author = {Goyette, Marie-Anne and Stevens, Laura E and DePinho, Carolyn R and Seehawer, Marco and Nishida, Jun and Li, Zheqi and Wilde, Callahan M and Li, Rong and Qiu, Xintao and Pyke, Alanna L and Zhao, Stephanie and Lim, Klothilda and Tender, Gabrielle S and Northey, Jason J and Riley, Nicholas M and Long, Henry W and Bertozzi, Carolyn R and Weaver, Valerie M and Polyak, Kornelia},
  title = {Cancer–stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2024},
  doi = {10.1073/pnas.2322688121}
}
Kostenlos starten →